Therapy Areas: Oncology
Results From Phase 3 PROpel Trial of Lynparza Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
23 June 2022 - - Results from the Phase 3 PROpel trial have been published in NEJM Evidence, British pharmaceutical company AstraZeneca and US-based pharmaceutical company Merck (NYSE: MRK) said.

Results from the trial showed that Lynparza in combination with abiraterone plus prednisone significantly improved radiographic progression-free survival versus abiraterone plus prednisone, a standard of care, as first-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) with or without homologous recombination repair gene mutations.

Globally, prostate cancer is the second most common cancer in patients assigned male at birth, with an estimated 1.4m patients diagnosed worldwide in 2020.

Approximately 10-20% of patients with advanced prostate cancer are estimated to develop CRPC within five years, and at least 84% of these patients may develop metastases at the time of CRPC diagnosis.

Patients with advanced prostate cancer have a particularly poor prognosis, and the five-year survival rate remains low.

In September 2021, at a planned interim analysis, the independent Data Monitoring Committee concluded that the PROpel trial met its primary endpoint of rPFS.

The results were presented in February 2022 at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, and additional data on safety and tolerability as well as pharmacokinetics were presented at the 2022 ASCO annual meeting on June 6.

As previously reported, in the Phase 3 PROpel trial, Lynparza in combination with abiraterone plus prednisone (n=399) reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p
Login
Username:

Password: